Fact checked by Nick Blackmer The Food and Drug Administration (FDA) recently approved a new targeted chemotherapy drug for ...

The shortage of generic chemotherapy drugs cisplatin and carboplatin that began in early 2023 did not increase short-term ...

A new treatment for colorectal cancer that has spread to the liver is showing promising results in Dutch medical trials. The ...

In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine (T-DM1) reduced the long-term risk of death or invasive disease by 46% and ...

Four in every 10 cancer patients treated with chemotherapy develop severe peripheral nerve pain, a new review suggests.

Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist at Mayo Clinic, suggests that medical providers can reduce patient ...

Chemotherapy has been known to cause damage to peripheral nerves, and sometimes the pain is chronic and severe enough that chemotherapy doses are reduced or discontinued. But prior research has not ...

The FDA clearance aids AstraZeneca and Daiichi Sankyo’s plan to position ADCs like Enhertu ahead of chemotherapy in a variety ...

Worldwide, cancer chemotherapy is linked to persistent severe peripheral nerve pain (neuropathy) for around 4 in every 10 patients treated with these drugs, suggests a pooled data analysis of the ...

A new drug delivery system shows promise for treating a rare, aggressive form of cancer affecting pregnant women and new mothers, and it has potential with other cancers as well.

Treosulfan (Grafapex) was approved in Canada in June 2021 for the same use and is marketed under the brand name Trecondyv.

Metronomic chemotherapy (MC) is emerging as a groundbreaking treatment for pediatric neuroblastoma, offering a more accessible and manageable option for children with high-risk and relapsed/refractory ...